KETAMINE: A POTENTIAL RAPID-ACTING ANTISUICIDAL AGENT?

Depression and Anxiety

Volumn 33, Issue 8, 2016, Pages 711-717

  Wilkinson, Samuel T ^a   Sanacora, Gerard ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antidepressant; depression; ketamine; suicidal ideation; suicide

Indexed keywords

ESCITALOPRAM; KETAMINE; MIDAZOLAM; PLACEBO;

BECK DEPRESSION INVENTORY; BECK SCALE FOR SUICIDAL IDEATION; BEHAVIOR ASSESSMENT; BIPOLAR DISORDER; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; TREATMENT RESISTANT DEPRESSION;

EID: 84979659188     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22498     Document Type: Review

References (41)

1. Centers for Disease Control and Prevention. Fatal Injury Report. 2014. Available at: http://www.cdc.gov/injury/wisqars/fatal_injury_reports.html, accessed January 20, 2016.
2. Aleman A, Denys D. Mental health: A road map for suicide research and prevention. Nature 2014;509(7501):421–423.
3. Griffiths JJ, Zarate CA Jr., Rasimas JJ. Existing and novel biological therapeutics in suicide prevention. Am J Prev Med 2014;47(3 Suppl 2):S195–S203.
4. American Foundation for Suicide Prevention. Suicide Statistics. 2016. Available at: http://afsp.org/about-suicide/suicide-statistics/, accessed January 26, 2016.
5. U.S. Public Health Service. The Surgeon General's Call to Action to Prevent Suicide. Washington, DC: US Public Health Service; 1999.
6. Bertolote JM, Fleischmann A. Suicide and psychiatric diagnosis: a worldwide perspective. World Psychiatry 2002;1(3):181–185.
7. Conwell Y, Duberstein PR, Cox C, et al. Relationships of age and axis I diagnoses in victims of completed suicide: a psychological autopsy study. Am J Psychiatry 1996;153(8):1001–1008.
8. Cavanagh JT, Carson AJ, Sharpe M, Lawrie SM. Psychological autopsy studies of suicide: a systematic review. Psychol Med 2003;33(3):395–405.
9. Holma KM, Melartin TK, Haukka J, et al. Incidence and predictors of suicide attempts in DSM-IV major depressive disorder: a five-year prospective study. Am J Psychiatry 2010;167(7):801–808.
10. Gibbons RD, Brown CH, Hur K, et al. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012;69(6):580–587.
11. Carpenter DJ, Fong R, Kraus JE, et al. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials. J Clin Psychiatry 2011;72(11):1503–1514.
12. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004;292(3):338–343.
13. Perlis RH, Beasley CM Jr., Wines JD Jr., et al. Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. Psychother Psychosom 2007;76(1):40–46.
14. Al Jurdi RK, Swann A, Mathew SJ. Psychopharmacological agents and suicide risk reduction: ketamine and other approaches. Curr Psychiatry Rep 2015;17(10):81.
15. Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013;346:f3646.
16. Mann JJ. Neurobiology of suicidal behaviour. Nat Rev Neurosci 2003;4(10):819–828.
17. Kellner CH, Fink M, Knapp R, et al. Relief of expressed suicidal intent by ECT: a consortium for research in ECT study. Am J Psychiatry 2005;162(5):977–982.
18. The Joint Commission Sentinel Event Statistics. Available at: http://www.jointcommission.org/sentinel_event.aspx, accessed March 1, 2016.
19. National Action Alliance for Suicide Prevention: Research Prioritization Task Force. A prioritized research agenda for suicide prevention: an action plan to save lives. Rockville, MD: National Institute of Mental Health and the Research Prioritization Task Force; 2014.
20. Reinstatler L, Youssef NA. Ketamine as a potential treatment for suicidal ideation: a systematic review of the literature. Drugs R D 2015;15(1):37–43.
21. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47(4):351–354.
22. Zarate CA Jr., Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63(8):856–864.
23. Zarate CA Jr., Brutsche NE, Ibrahim L, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012;71(11):939–946.
24. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010;67(8):793–802.
25. Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013;170(10):1134–1142.
26. Newport DJ, Carpenter LL, McDonald WM, et al. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry 2015;172(10):950–966.
27. DiazGranados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010;71(12):1605–1611.
28. Thakurta RG, Das R, Bhattacharya AK, et al. Rapid response with ketamine on suicidal cognition in resistant depression. Indian J Psychol Med 2012;34(2):170–175.
29. Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009;66(5):522–526.
30. Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2013;74(4):250–256.
31. Rasmussen KG, Lineberry TW, Galardy CW, et al. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol 2013;27(5):444–450.
32. Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 2011;14(8):1127–1131.
33. Kashani P, Yousefian S, Amini A, et al. The effect of intravenous ketamine in suicidal ideation of emergency department patients. Emergency (Tehran) 2014;2(1):36–39.
34. Ballard ED, Ionescu DF, Vande Voort JL, et al. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res 2014;58:161–166.
35. Ballard ED, Luckenbaugh DA, Richards EM, et al. Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant. J Psychiatr Res 2015;68:68–73.
36. Hu YD, Xiang YT, Fang JX, et al. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Psychol Med 2015;108(3):1–13.
37. Price RB, Iosifescu DV, Murrough JW, et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety 2014;31(4):335–343.
38. Murrough JW, Soleimani L, DeWilde KE, et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med 2015;45(16):1–10.
39. Price RB, Mathew SJ. Does ketamine have anti-suicidal properties? Current status and future directions. CNS Drugs 2015;29(3):181–188.
40. Laughren TP. Comorbid mood disorders and medical illness: a food and drug administration perspective. Biol Psychiatry 2003;54(3):195–199.
41. Laughren T, Levin R. Food and drug administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. Schizophr Bull 2006;32(2):220–222.